Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is a human cell surface protein expressed exclusively on eosinophils, mast cells, and basophils that, when engaged, induces eosinophil apoptosis and inhibits mast cell mediator release. This makes Siglec-8 a promising therapeutic target to treat diseases involving these cell types. However, preclinical studies of Siglec-8 targeting in vivo are lacking because this protein is only found in humans, apes, and some monkeys. Therefore, we have developed a mouse strain in which SIGLEC8 transcription is activated by Cre recombinase and have crossed this mouse with the eoCre mouse to achieve eosinophil-specific expression. We confirmed that Siglec-8 is expressed exclusively on the surface of mature eosinophils in multiple tissues at levels comparable to those on human blood eosinophils. Following ovalbumin sensitization and airway challenge, Siglec-8 knock-in mice generated a pattern of allergic lung inflammation indistinguishable from that of littermate controls, suggesting that Siglec-8 expression within the eosinophil compartment does not alter allergic eosinophilic inflammation. Using bone marrow from these mice, we demonstrated that, during maturation, Siglec-8 expression occurs well before the late eosinophil developmental marker C-C motif chemokine receptor 3, consistent with eoCre expression. Antibody ligation of the receptor induces Siglec-8 endocytosis and alters the phosphotyrosine profile of these cells, indicative of productive signaling. Finally, we demonstrated that mouse eosinophils expressing Siglec-8 undergo cell death when the receptor is engaged, further evidence that Siglec-8 is functional on these cells. These mice should prove useful to investigate Siglec-8 biology and targeting in vivo in a variety of eosinophilic disease models.
F I G U R E 1 Generation of the SIGLEC8 Eo mouse. The SIGLEC8 gene was introduced by homologous recombination into the Rosa26 locus with an upstream floxed STOP cassette (LSL). Following crossing this mouse with one expressing Cre recombinase under the control of the eosinophil peroxidase (EPX) promoter, Cre-mediated excision of the STOP cassette permitted Siglec-8 expression only in cells expressing EPX we describe the methods used to generate this SIGLEC8 Eo mouse strain and provide data from our initial characterization of Siglec-8 expression, function, and modulation of immune responses in these mice.
MATERIALS AND METHODS

Mice
Knock-in mice (SIGLEC8 LSL ) were generated by homologous recombination on a C57BL/6 genetic background using a targeting construct ( 
Flow cytometric analysis of surface phenotype and apoptosis
Gut lamina propria was isolated using the Lamina Propria Dissociation Kit from Miltenyi Biotec (Bergisch Gladbach, Germany) according to the manufacturer's instructions, and the epithelial fraction was saved for flow cytometric analysis as well. Spleen and bone marrow were dissociated into single-cell suspensions prior to staining. Blood and peritoneal lavage fluid were collected. Cells were stained (antibody information is included in Table 1 ) and analyzed on an LSR II flow cytometer (BD Biosciences, San Jose, CA) using FlowJo v.10.0.8 (Tree Star, Ashland, OR). Endocytosis of Siglec-F and Siglec-8 was followed using flow cytometry by engaging and labeling the proteins with unlabeled antibodies and detecting the remaining surface-bound antibody after incubations of various durations at 37 • C with labeled secondary antibodies. Isotype controls were used to determine staining background. Eosinophil cell death was detected using fluorophore-labeled annexin V (BD Biosciences) and 4 ′ ,6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific, Waltham, MA) following 18-24 h of culture with unlabeled anti-Siglec-8, anti-Siglec-F, or their isotype-matched control mAbs at 2.5 g/ml.
Eosinophil differentiation from bone marrow precursors
Eosinophils were generated from bone marrow from SIGLEC8 Eo mice using a protocol described by Dyer et al. 16 Bone marrow-derived eosinophil (BMDE) development and viability was assessed by flow cytometry with antibodies against Siglec-8, Siglec-F, and C-C motif chemokine receptor 3 (CCR3; BD Pharmingen, San Diego, CA) and DAPI (Thermo Fisher Scientific).
Phosphotyrosine western blot
Following antibody engagement of Siglec-8 or Siglec-F on BMDEs for 1 h at 37 • C, global tyrosine phosphorylation changes were detected by western blot. Proteins were separated on 4-15% gradient mini-PROTEAN TGX precast gels and transferred to Immun-Blot PVDF membranes using the Trans-Blot SD semi-dry transfer cell (Bio-Rad, Hercules, CA). The 4G10 platinum anti-phosphotyrosine mAb (Millipore, Billerica, MA) was used at a 1:1000 dilution. Anti--actin (Thermo Scientific) was used to indicate equal loading. IRDye 680RD-or 800RD-conjugated secondary antibodies (LI-COR, Lincoln, NE) were used, and images and quantification were obtained using the Odyssey Imaging System (LI-COR).
Reactive oxygen species generation assay
Following antibody engagement of Siglec-8 or Siglec-F on BMDEs for the indicated durations at 37 • C, total reactive oxygen species (ROS) production was determined using the ROS-ID Total ROS detection kit (Enzo Life Sciences, Farmingdale, NY) by flow cytometry. ROS levels are presented as a percentage of the levels observed with the positive control (pyocyanin). 
OVA asthma model
Statistical analysis
Data were analyzed and t-tests and Tukey multiple comparisons tests were performed using GraphPad Prism v6.0 (La Jolla, CA). Differences between means were considered statistically significant when P < 0.05.
RESULTS
We introduced cDNA encoding the full-length form of Siglec-8 into the first intron of the Rosa26 genomic locus by homologous recombination to generate a mouse strain capable of expressing the human receptor Siglec-8 ( Fig. 1) . Upstream of the SIGLEC8 gene, we placed a loxP-flanked STOP cassette (LSL) that would prevent expression of this gene except in cells also expressing Cre recombinase. We have referred to this recombined locus as SIGLEC8 LSL . Expression of Siglec-8 on eosinophil-lineage committed cells was achieved by crossing these mice with a previously published strain on the C57BL/6 background in which Cre recombinase expression is driven by the EPX promoter (eoCre) 15 to generate SIGLEC8 Eo mice.
We first sought to confirm that Siglec-8 expression was restricted to eosinophils in mice possessing both of these recombinant loci.
We examined cells in the blood, spleen, bone marrow, peritoneal lavage, and gut by flow cytometry. We confirmed that Siglec-8 was restricted to eosinophils (i.e., SSC hi /CD45 + /Siglec-F + cells) and that it was expressed by all eosinophils examined in these tissues at levels similar to those seen on human eosinophils (Fig. 2) . In addition to eosinophils, alveolar macrophages and subtypes of gut epithelial cells also express Siglec-F in the mouse. [17] [18] [19] However, Siglec-F + gut epithelial cells, as expected, do not express Siglec-8 ( expressed at the developmental stage preceding Siglec-F expression or earlier but began to be expressed at the eosinophil progenitor stage, at which point the cells begin to express Siglec-F and become granular (Fig. 3B) , consistent with the in vitro differentiation results.
Next, we engaged the Siglec-8 receptor on BMDEs using an anti-Siglec-8 mAb (clone 2C4) to establish whether Siglec-8 was capable of signaling on these cells. First, we compared general tyrosine phosphorylation and receptor endocytosis induced by this treatment with anti-Siglec-F (clone 9C7) or isotype control mAbs treatments.
While anti-Siglec-F did not appreciably alter downstream tyrosine phosphorylation as determined by pan-phosphotyrosine blot and caused Siglec-F to be internalized slowly, Siglec-8 ligation induced distinct patterns of tyrosine phosphorylation and caused Siglec-8 to be endocytosed more rapidly, indicating that the receptor is capable of transducing a signal on these cells ( Fig. 4A and B) . The presence of a secondary crosslinking antibody did not augment 2C4-induced signaling but did appear to induce 9C7-dependent tyrosine phosphorylation through Siglec-F (Fig. 4A) . Siglec-F antibody ligation did not Fig. S2 ). However, Siglec-8 ligation on these cells also failed to induce ROS production within a 2 h timeframe ( Supplementary Fig. S2 ). To determine whether Siglec-8 expression on mouse eosinophils perturbs eosinophil number, survival, or tissue trafficking in the absence of any intervention with antibody or ligand for Siglec-8, we utilized a chicken ovalbumin (OVA)-driven model of allergic respiratory inflammation. SIGLEC8 Eo mice and littermate controls were sensitized to OVA and challenged with nebulized OVA or, as a negative control, with nebulized HBSS vehicle. We harvested blood, bone marrow, and BAL fluid from the mice 96 h after the last challenge. As expected, we found that eosinophils had migrated to the lungs as a result of the OVA challenges (Fig. 5A) . Consistent with the lack of eosinophil peroxidase expression in Siglec-F + alveolar macrophages, there was no Siglec-8 expression observed in these cells (data not shown). In addition, there were trends toward increases of eosinophil levels in the blood and bone marrow, consistent with the effects of this allergen sensitization/challenge model ( Fig. 5B and C). However, there were no statistically significant differences between the SIGLEC8 Eo mice and the littermate controls ( Fig. 5A-C) ,
indicating that the presence of the human Siglec-8 receptor on these cells did not have an impact on eosinophil numbers or tissue homing.
Additionally, histological staining of lung tissue demonstrated that lung inflammation and goblet cell hyperplasia were not appreciably affected by the expression of Siglec-8 on eosinophils ( Fig. 5D and E) .
Finally, we examined whether Siglec-8 engagement on mouse eosinophils could induce cell death as it does on human eosinophils. To do this, we isolated eosinophils from the blood and spleens of SIGLEC Eo mice. We cultured these cells overnight with antibodies to Siglec-8 or
Siglec-F or with appropriate isotype controls before assessing the proportion of remaining eosinophils, siglec internalization, and eosinophil cell death by flow cytometry. We found that anti-Siglec-8 antibody treatment potently depleted eosinophils as a percentage of CD11b-expressing cells in the blood and spleen (Fig. 6A and B and data not shown). In addition, nearly all of the remaining eosinophils in the samples treated with anti-Siglec-8 underwent cell death ( Fig. 6C and D) .
Anti-Siglec-F antibody treatment caused trends toward decreases in the proportion of remaining eosinophils and decreases in cell viability in the remaining eosinophils, but these effects were not statistically significant despite an apparent decrease in unbound surface Siglec-F caused by the antibody treatment ( Fig. 6A-D) .
DISCUSSION
We describe a novel mouse strain in which the human protein Siglec-8
was expressed consistently and exclusively in the eosinophil compartment. In the blood, bone marrow, spleen, peritoneal cavity, and gut lamina propria, Siglec-8 expression was observed on all eosinophils examined and only on eosinophils. That is, no Siglec-8 was detected on any other cell type, including other cell types that express Siglec-F, such as alveolar macrophages or specific subtypes of gut epithelial cells. [17] [18] [19] engages the same endocytic machinery, both of which have recently been described. [21] [22] [23] Given the weak pro-apoptotic effects of Siglec-F compared to the robust response to Siglec-8, it is tempting to speculate that these pathways will turn out to be distinct. Ultimately, the ability to cross this mouse with strains lacking particular signaling molecules, endocytic components, or cell death effectors may well provide additional insight into the mechanisms employed by Siglec-F and Siglec-8, and this will be the focus of future studies.
One explanation for the lack of effect of the introduction of Siglec-8 on eosinophil numbers in this mouse strain is that mice may lack glycan ligands for Siglec-8. Indeed, while Siglec-8 and Siglec-F share similar glycan binding profiles, Siglec-F recognizes certain branched structures not recognized by Siglec-8. 11,13 Furthermore, the endogenous ligands for each of these receptors appear to be distinct. Siglec-F recognizes glycans displayed on mouse Muc5b from upper airway mucosa, 13 but Siglec-8 fails to recognize human MUC5B and does not recognize any mouse airways structures. 24, 25 Siglec-8 has an absolute requirement for seeing 2,3-linked, 6 ′ -sulfated ligands, while Siglec-F binding is more promiscuous and may not require sulfation. 13, 26, 27 In the absence of endogenous ligand, the engineered expression of Siglec-8 may exert no new biological effect in vivo on these cells.
Although this system may not lend itself to the study of Siglec-8 biology in response to endogenous signals and tissue-derived ligands, this new mouse strain is ideal to study the efficacy and consequences of targeting Siglec-8 with specific antibodies or ligand-based agents, such as nanoparticles decorated with Siglec-8-specific glycan or glycomimetic ligands, due to the lack of baseline differences between mice that express Siglec-8 and those that do not. Based on the distinct lung eosinophilia following allergen sensitization and challenge, 28, 29 but whether the substitution of Siglec-8 for Siglec-F will rescue this phenotype remains to be determined. Interestingly, targeting Siglec-F on mouse eosinophils failed to achieve the same effects as targeting Siglec-8 in this study. As mentioned above, ligation of Siglec-F results in a much weaker cell death effect on mouse eosinophils than Siglec-8 exerts on, in particular, IL-5-primed human eosinophils. 12, 30, 31 However, antibody ligation of Siglec-F can rapidly clear circulating eosinophils and reduces eosinophilic inflammation, 30, 32, 33 and loss of endogenous sialoside ligands for Siglec-F exacerbates eosinophilic inflammation. 34, 35 This study used a distinct anti-Siglec-F mAb clone (9C7, rat IgG2b) 18 
